ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

Core Points - ReShape Lifesciences Inc. has regained compliance with Nasdaq's stockholders equity requirement, closing the listing matter [1][2] - The company previously faced potential delisting due to non-compliance with the minimum stockholders' equity requirement of $2.5 million [2] - As of March 31, 2025, the company's stockholders' equity was reported at $1.2 million [3] - The company raised a total of approximately $6.3 million through the sale of common stock in June 2025, which helped it regain compliance [3] Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products and services for obesity and metabolic disease management [4] - The company provides the FDA-approved Lap-Band® System, which is a minimally invasive treatment for obesity [4] - Other offerings include an investigational vagal neuromodulation system for type 2 diabetes and metabolic disorders, and the non-surgical Obalon® balloon technology for weight loss [4]